InterMune, Inc. has closed its exclusive license and collaboration agreement with Roche for the exclusive worldwide development and commercialization of InterMune’s hepatitis C virus (HCV) protease inhibitor program. The parties received notice of early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, on October 30th. As a result of the closing, InterMune will receive an upfront payment of $60 million. Roche is now funding 67% of the glo...